Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.

@article{Sermet2010OngoingPR,
  title={Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.},
  author={Catherine Sermet and V{\'e}ronique Andrieu and Brian B Godman and Eric Van Ganse and Alan Haycox and Jean-Pierre Reynier},
  journal={Applied health economics and health policy},
  year={2010},
  volume={8 1},
  pages={7-24}
}
The rapid rise in pharmaceutical costs in France has been driven by new technologies and the growing prevalence of chronic diseases as well as considerable prescribing freedom and choice of physician among patients. This has led to the introduction of a number of reforms and initiatives in an attempt to moderate expenditure whilst ensuring universal coverage and rewarding innovation. These reforms include accelerating access to and granting average European prices for new innovative drugs… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

Similar Papers

Loading similar papers…